Compare Abbott Laboratories (ABT) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Hims and Hers Health Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Hims and Hers Health Inc trades at $34.92 (market cap $8.37B). The key difference: Abbott Laboratories is far larger — about 19.9× Hims and Hers Health Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| ABT | HIMS | |
|---|---|---|
Market Cap | $166.94B | $8.37B |
Sector | Health | Health |
52-Week High | $136.62 | $66.18 |
52-Week Low | $82.57 | $14.52 |
Enterprise Value | $193.69B | $8.75B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Hims & Hers Health trades at $38.28, up 4.02% today, showing strong momentum near its 52-week high. The stock exhibits a bullish technical trend with support at $37 and resistance at $39. Fundamentally, revenue reached $2.35 billion in 2025 with a gross margin of 71.72%, though net income turned negative in 2026. Recent news highlights growth in weight-loss subscriptions and a price target increase from Canaccord Genuity to $40 (July 1, 2026).
The outlook is mixed: bullish technicals and subscriber growth contrast with high valuation multiples (P/E 57.14) and recent earnings misses. Key risks include execution in competitive telehealth and reliance on obesity drug trends. Analysts are cautious with 65% hold ratings, consensus target $33.43 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
